The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Gilead Joining the Global Access to Oncology Medicines Coalition

By: 3BL Media

SOURCE: Gilead Sciences

DESCRIPTION:

We’re pleased to announce that we're joining the global Access to Oncology Medicines (ATOM) Coalition to help improve care and access to essential cancer medicines in low- and lower middle-income countries. https://gilead.inc/39Gb9nb

About Gilead

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

View original content here

Tweet me: .@GileadSciences announces they are joining the global Access to Oncology Medicines (ATOM) Coalition. Read more here: https://bit.ly/3PHkf3F

KEYWORDS: NYSE: GILD, Gilead Sciences, ATOM

"Making strides against cancer in low- and lower middle- income countries will require not only innovative therapies, but also bold strategies built on the power of partnerships and working across the continuum of care - starting from disease awareness and prevention, to diagnosis and treatment, all the way to disease management." Mike Boyd Senior Vice President Gilead logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.